Mark Jeffrey Delong Sells 3,371 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 3,371 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $73,386.67. Following the completion of the transaction, the insider owned 78,353 shares of the company’s stock, valued at approximately $1,705,744.81. This trade represents a 4.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Mark Jeffrey Delong also recently made the following trade(s):

• On Tuesday, January 20th, Mark Jeffrey Delong sold 1,334 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $19.79, for a total transaction of $26,399.86.
• On Tuesday, January 13th, Mark Jeffrey Delong sold 1,780 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total value of $39,498.20.

Apellis Pharmaceuticals Trading Down 1.1%

NASDAQ APLS opened at $21.76 on Friday. Apellis Pharmaceuticals, Inc. has a 12 month low of $16.10 and a 12 month high of $30.91. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $2.75 billion, a PE ratio of 70.18 and a beta of 0.31. The business’s 50-day moving average price is $23.02 and its two-hundred day moving average price is $23.56.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million for the quarter, compared to analysts’ expectations of $364.58 million. During the same period in the prior year, the business posted ($0.46) earnings per share. The firm’s revenue was up 133.0% on a year-over-year basis. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Wells Fargo & Company decreased their price target on shares of Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating for the company in a research note on Tuesday, January 20th. Citigroup cut their price objective on shares of Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Wolfe Research initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 6th. They issued a “peer perform” rating for the company. Finally, Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Twelve equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.53.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its stake in shares of Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after purchasing an additional 855 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Apellis Pharmaceuticals by 206.8% during the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after buying an additional 1,373 shares in the last quarter. Osaic Holdings Inc. raised its position in Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after buying an additional 1,570 shares during the last quarter. Allworth Financial LP lifted its stake in Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after acquiring an additional 857 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Apellis Pharmaceuticals during the 3rd quarter worth $64,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.